Advancements in Gene Therapy for Type 2 Diabetes: Insights from CRISPR Cas9 Mediated Gene Editing and Insulin Production
Abstract
This literature presents a comprehensive overview of the application of CRISPR-based gene editing technology in the treatment of diabetes mellitus (DM). The introduction highlights the significance of DM as one of the oldest human diseases and the need for effective control to prevent potential consequences. It emphasizes the limitations of conventional medications for hyperglycemia and the challenges in achieving optimal glucose concentrations and minimizing long-term consequences. The abstract then delves into the advancements in CRISPR technology, discussing various delivery methods for the CRISPR-Cas complex, including non-viral vectors, viral vectors, and nanocarriers. The use of CRISPR-Cpf1 as an alternative to Cas9 is explored, highlighting its advantages and functionality. The abstract further explores the potential of CRISPR gene therapy and nanocarriers in treating DM, particularly targeting the NLRP3 inflammasome and downregulating the DPP-4 enzyme. Liposomal particles and lecithin nano-liposomal particles are discussed as efficient delivery systems for CRISPR/Cas9, with potential applications in T2DM treatment. The role of islet amyloid polypeptide (IAPP) in T2DM and its study using CRISPR Cas9-based gene editing technology is also presented. Overall, this abstract provides a comprehensive overview of the current advancements and potential applications of CRISPR technology in the treatment of DM.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.